Beam Therapeutics (BEAM) CMO sells 16,667 shares under 10b5-1 plan

Rhea-AI Filing Summary

Beam Therapeutics Inc. reports that Chief Medical Officer Simon Amy sold 16,667 shares of common stock on July 27, 2026 at a weighted average price of $25.7417 per share, in multiple trades between $25.32 and $26.05, under a Rule 10b5-1 trading plan adopted on March 27, 2026. Following these sales, the reporting person directly owns 85,696 shares of Beam Therapeutics common stock.

Insider Trade Summary 10b5-1

Net Seller: 16,667 shares

Net Sell 1 txn

Insider Simon Amy

Role Chief Medical Officer

Sold 16,667 shs ($429K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	16,667	$25.7417	$429K

Holdings After Transaction: Common Stock — 85,696 shares (Direct)

Footnotes (2)

1. F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $25.32 to $26.05, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares sold: 16,667 shares Weighted average sale price: $25.7417 per share Sale price range: $25.32–$26.05 per share +2 more

5 metrics

Shares sold 16,667 shares Common stock sold on July 27, 2026

Weighted average sale price $25.7417 per share Weighted average price for the 16,667 shares sold

Sale price range $25.32–$26.05 per share Range of prices for multiple sale transactions

Shares held after transaction 85,696 shares Direct ownership following the July 27, 2026 sale

10b5-1 plan adoption date March 27, 2026 Date the Rule 10b5-1 trading plan was adopted

Key Terms

Rule 10b5-1 trading plan, weighted average price, open market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction financial

"Transaction code description: Sale in open market or private transaction"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/29/2026 - 04:05 PM Accepted by SEC EDGAR 07/29/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What insider transaction did BEAM report for Simon Amy?

Beam Therapeutics reported that Chief Medical Officer Simon Amy sold 16,667 shares of common stock on July 27, 2026. The transaction was executed as a planned sale under a Rule 10b5-1 trading plan adopted on March 27, 2026.

At what price were the BEAM shares sold in this Form 4?

The shares were sold at a weighted average price of $25.7417 per share. According to the disclosure, individual trades occurred in multiple transactions at prices ranging from $25.32 to $26.05 per share, inclusive.

How many BEAM shares does Simon Amy hold after the reported sale?

After the reported sale, Simon Amy directly holds 85,696 shares of Beam Therapeutics common stock. This post-transaction figure reflects holdings immediately following the disposition of 16,667 shares disclosed in the Form 4.

Was the BEAM insider sale made under a Rule 10b5-1 plan?

Yes. The transactions were carried out under a Rule 10b5-1 trading plan adopted by the reporting person on March 27, 2026. Such plans allow pre-arranged trades, which can reduce the significance of transaction timing for interpreting insider intent.

What is Simon Amy's role at Beam Therapeutics (BEAM)?

The reporting person, Simon Amy, serves as Chief Medical Officer of Beam Therapeutics. This executive position oversees the company's medical and clinical activities and is identified as an officer role in the insider ownership disclosure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simon Amy

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/27/2026		S(1)		16,667	D	$25.7417(2)	85,696	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $25.32 to $26.05, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

	By: /s/ Christine Bellon, Attorney-in-fact	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)